PHIO PHARMACEUTICALS CORP

PHIO insider buying surge: executives stake 6% in the stock amid promising oncology pipeline and FDA fast‑track approval hopes.

Insider buys of Phio Pharmaceuticals’ RSUs signal confidence, yet dilution risks loom as the company ramps up its incentive plan amid volatile biotech markets.

Phio Pharmaceuticals’ insider buying signals confidence amid a tough market: owner Patricia Bradford’s small, steady purchases suggest the stock is undervalued and could rise with upcoming clinical and FDA milestones.

Phio Pharmaceuticals CEO buys 2,000 shares amid mixed insider trading—an insider confidence signal that could help stabilize its struggling cancer‑immunotherapy stock.

Phio Pharmaceuticals’ insider buying shows senior confidence despite a flat share price; learn how Patricia Bradford’s recent purchase signals long‑term potential in their oncology pipeline.

PHIO Pharmaceuticals insider sale: CEO Bitterman sells 68,550 shares for tax reasons, no shift in strategy. Focus on PH‑762 clinical progress & potential upside.